MRZM Stock Overview
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Marizyme, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.44 |
| 52 Week High | US$3.25 |
| 52 Week Low | US$0.28 |
| Beta | 0.47 |
| 1 Month Change | -30.59% |
| 3 Month Change | n/a |
| 1 Year Change | -76.08% |
| 3 Year Change | -84.36% |
| 5 Year Change | -4.63% |
| Change since IPO | -74.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRZM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.5% | -0.3% | 1.7% |
| 1Y | -76.1% | 5.3% | -9.1% |
Return vs Industry: MRZM underperformed the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: MRZM underperformed the US Market which returned -9.1% over the past year.
Price Volatility
| MRZM volatility | |
|---|---|
| MRZM Average Weekly Movement | 45.7% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MRZM is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 46% a week.
Volatility Over Time: MRZM's weekly volatility has increased from 28% to 46% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 11 | David Barthel | https://marizyme.com |
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth.
Marizyme, Inc. Fundamentals Summary
| MRZM fundamental statistics | |
|---|---|
| Market Cap | US$18.07m |
| Earnings (TTM) | -US$20.12m |
| Revenue (TTM) | US$76.15k |
237.3x
P/S Ratio-0.9x
P/E RatioIs MRZM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRZM income statement (TTM) | |
|---|---|
| Revenue | US$76.15k |
| Cost of Revenue | -US$61.54k |
| Gross Profit | US$137.69k |
| Other Expenses | US$20.25m |
| Earnings | -US$20.12m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 180.81% |
| Net Profit Margin | -26,417.82% |
| Debt/Equity Ratio | 4.5% |
How did MRZM perform over the long term?
See historical performance and comparison